| Serial Number | 97760513 |
| Word Mark | QUAISAR DRUG DESIGN PLATFORM |
| Filing Date | Thursday, January 19, 2023 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Saturday, June 15, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Downloadable and recorded computer software for providing, analyzing and generating reports; downloadable and recorded computer software for data processing; electronic apparatus, electronic equipment, downloadable and recorded software, programs and systems for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and/or transmission of data, images and information; downloadable and recorded computer software for database integration; downloadable and recorded software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; downloadable and recorded software for genetic assessment and identification of diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; downloadable and recorded software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical data and images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable and recorded software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement |
| NOT AVAILABLE | "DRUG DESIGN PLATFORM" |
| Goods and Services | Scientific and technological services and research and design in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; analyzing of technical scientific and pharmaceutical research data by computers; Pharmaceutical drug discovery services; pharmaceutical and biotechnology research and development services; drug discovery services; design and development of pharmaceutical preparations and medicines; research and development in the field of drug discovery; conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; analyzing scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; bioinformatics services, namely, using the combination of biology, computer science, information engineering, mathematics and statistics to analyse and interpret biological data; computer assisted molecule design; scientific and biological research, namely, identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic for scientific research purposes; computer aided scientific screening services for scientific research purposes; contract scientific research services in support of scientific research and development of pharmaceutical preparations; software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; software as a service (SaaS) for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software as a service (SaaS) for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement |
| International Class | 009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus. |
| US Class Codes | 021, 023, 026, 036, 038 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 8, 2023 |
| Primary Code | 009 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 8, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | PSIVANT THERAPEUTICS, INC. |
| Party Type | 12 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | BOSTON, MA 02210 |
| Party Name | ROIVANT DISCOVERY, INC. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | BOSTON, MA 02210 |
| Party Name | Roivant Sciences GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Basel 4051 CH |
| Event Date | Event Description |
| Monday, January 23, 2023 | NEW APPLICATION ENTERED |
| Wednesday, February 8, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 31, 2023 | ASSIGNED TO EXAMINER |
| Monday, July 17, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, July 17, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, July 17, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, October 4, 2023 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Monday, October 16, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, October 16, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, January 17, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, January 17, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 18, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 3, 2024 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Saturday, June 15, 2024 | FINAL REFUSAL E-MAILED |
| Saturday, June 15, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Saturday, June 15, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, September 12, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Thursday, September 12, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |